FY2025 EPS Estimates for ARWR Decreased by Cantor Fitzgerald

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Cantor Fitzgerald lowered their FY2025 EPS estimates for Arrowhead Pharmaceuticals in a note issued to investors on Wednesday, September 10th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnings per share of ($0.94) for the year, down from their prior forecast of ($0.54). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals’ FY2026 earnings at ($2.24) EPS.

ARWR has been the topic of a number of other research reports. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 18th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 2nd. Royal Bank Of Canada dropped their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Finally, TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $29.72 on Friday. The firm has a market capitalization of $4.11 billion, a P/E ratio of -23.22 and a beta of 1.00. The firm’s 50 day moving average is $19.99 and its 200-day moving average is $16.55. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $31.13. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the company earned ($1.38) EPS.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ARWR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after purchasing an additional 2,774,933 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares during the period. Norges Bank acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at $30,414,000. Vanguard Group Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after acquiring an additional 1,018,273 shares during the period. Finally, Aberdeen Group plc boosted its holdings in shares of Arrowhead Pharmaceuticals by 138.4% during the first quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company’s stock valued at $13,668,000 after acquiring an additional 622,752 shares during the period. Institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total transaction of $375,000.00. Following the completion of the sale, the insider owned 247,122 shares in the company, valued at $6,178,050. The trade was a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 25,000 shares of company stock worth $575,000 in the last three months. 4.30% of the stock is owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.